Agenus Inc

-0.19 (-6.38%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)789.14M
Current PE80.27
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$19.86 Million
Adjusted EPS-$0.18
See more estimates
10-Day MA$2.81
50-Day MA$2.37
200-Day MA$2.63
See more pivots

Agenus Inc Stock, NASDAQ:AGEN

3 Forbes Road, Lexington, Massachusetts 02421-7305
United States of America
Phone: +1.781.674.4400
Number of Employees: 441


Agenus, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava in March 31, 1994 and is headquartered in Lexington, MA.